Patents by Inventor Emma Jenkins

Emma Jenkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SERUM HALF-LIFE EXTENDED PD-L1 BINDING POLYPEPTIDES
    Publication number: 20240409638
    Abstract: The present disclosure provides engineered PD-L1-binding Stefin A polypeptide variants, polynucleotides encoding the engineered PD-L1-binding Stefin A polypeptide variants, cells expressing the polypeptide variants, pharmaceutical preparations of the polypeptide variants, and uses of the polypeptide variants in the treatment of various human conditions, including cancer.
    Type: Application
    Filed: October 6, 2022
    Publication date: December 12, 2024
    Applicant: Avacta Life Sciences Limited
    Inventors: Amrik Basran, Emma Jenkins, Estelle Adam, Emma Stanley, Michele Writer
  • ANTI-UNC5C ANTIBODIES
    Publication number: 20240228604
    Abstract: Isolated antibodies which specifically bind to UNC5C protein and mimic and/or compete with Netrin-1 for binding to UNC5C are disclosed. Related products and uses including therapeutic uses in the treatment of neurodegenerative disorders are also disclosed.
    Type: Application
    Filed: January 9, 2024
    Publication date: July 11, 2024
    Inventors: Iosif Pediaditakis, Michelle Sidor, James McCarthy, Sandrine Legg, Giles Lewis, Laura Sophie Mitchell, Justin Barton, Emma Jenkins, Ralph Raymond Minter, Donna Finch, Jacob Daniel Galson, Jane Katharine Osbourn, Jorge Norman Dias Do Nascimento, Paulina Maria Kolasinska-Zwierz, William James Hawthorne
  • FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES
    Publication number: 20230390409
    Abstract: Disclosed herein are therapeutic conjugates having an extended circulating serum half-life. The therapeutic conjugates comprise a therapeutic moiety linked to a half-life extension moiety via a fibroblast activation protein, alpha (FAP?)-cleavable linker. Methods of using the therapeutic conjugates are also provided.
    Type: Application
    Filed: October 29, 2021
    Publication date: December 7, 2023
    Applicants: Avacta Life Sciences Limited, Trustees of Tufts College
    Inventors: Amrik Basran, Matthew P. Vincent, Emma Jenkins, Estelle Adam, William Bachovchin
  • ENZYME-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES
    Publication number: 20230381330
    Abstract: Disclosed herein are therapeutic conjugates having an extended circulating serum half-life. The therapeutic conjugates comprise a drug moiety linked to a half-life extension moiety via an enzyme-cleavable linker. Methods of using the therapeutic conjugates are also provided.
    Type: Application
    Filed: October 29, 2021
    Publication date: November 30, 2023
    Applicants: Avacta Life Sciences Limited, Trustees of Tufts College
    Inventors: Amrik Basran, Matthew P. Vincent, Emma Jenkins, Estelle Adam, William Bachovchin
  • SERUM ALBUMIN-BINDING POLYPEPTIDES
    Publication number: 20230272011
    Abstract: Provided herein, in some embodiments, are recombinantly engineered variant of stefin polypeptides (AFFIMER® polypeptides) that binds to human serum albumin and extends the half-life of the polypeptides. Also provided herein, in some embodiments, are composition containing the polypeptides, methods of using the polypeptides, and methods of producing the polypeptides.
    Type: Application
    Filed: July 30, 2021
    Publication date: August 31, 2023
    Applicant: Avacta Life Sciences Limited
    Inventors: Emma Jenkins, Estelle Adam, Emma Stanley, Amrik Basran, Matthew P. Vincent, Bruno Gomes
  • SERUM HALF-LIFE EXTENDED PD-L1 INHIBITORY POLYPEPTIDES
    Publication number: 20230272081
    Abstract: Provided herein, in some embodiments, are fusion proteins comprising recombinantly engineered variant of stefin polypeptide (an AFFIMER® polypeptide) that binds to PD-L1 and a polypeptide that binds to human serum albumin (HSA). Also provided herein, in some embodiments, are compositions containing the fusion proteins, methods of using the fusion proteins, and methods of producing the fusion proteins.
    Type: Application
    Filed: July 30, 2021
    Publication date: August 31, 2023
    Applicant: Avacta Life Sciences Limited
    Inventors: Emma Jenkins, Estelle Adam, Emma Stanley, Amrik Basran, Matthew P. Vincent
  • PD-L1 BINDING AFFIMERS, AND USES RELATED THERETO
    Publication number: 20210163599
    Abstract: The present disclosure relates to proteins including PD-L1 binding affimer polypeptide sequences, gene expression constructs encoded those proteins, cells expressing those proteins, and pharmaceutical preparations of those proteins, gene expression constructs and cells and use in the treatment of various human conditions including cancer.
    Type: Application
    Filed: April 11, 2019
    Publication date: June 3, 2021
    Applicant: Avacta Life Sciences Limited
    Inventors: Amrik Basran, Emma Jenkins, Estelle Adam, Michelle Writer, Emma Stanley